Publication of additional explanations on the GCR report. Clarifies the breakdown of consolidated results for the fiscal year ending March 2026, background of accounts receivable increases, and dividend treatment in individual financial statements, correcting points of discrepancy with facts.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4005","jir_company_name":"Sumitomo Chemical Company, Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-07","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4005-20260807-01.pdf","jir_short_summary":"Publication of additional explanations on the GCR report. Clarifies the breakdown of consolidated results for the fiscal year ending March 2026, background of accounts receivable increases, and dividend treatment in individual financial statements, correcting points of discrepancy with facts.","jir_summary":"### Overview\nThis additional explanation consolidates and publishes the views of Sumitomo Pharma and the group in response to the claims in Gotham City Research LLC's August 3 report. It presents concrete grounds to counter the asserted points regarding factors boosting profit for the fiscal year ending March 2026, suspicions of improper revenue recognition due to increases in accounts receivable, the legitimacy of dividend treatment in individual financial statements, and the financial reporting process.\n\n### Impact and Future\nWhile considering appropriate responses including potential legal action regarding the GCR report, we emphasize maintaining the reliability and transparency of financial reporting. For consolidation and individual accounting treatments, we explain their appropriateness under IFRS\/Japanese standards and commit to ongoing timely and appropriate disclosure.","jir_financial_highlights":"Consolidated earnings for the year ending March 2026 \u2013 noted items: Unknown (Unknown)\nFactors behind increase in accounts receivable balance: Unknown (Unknown)\nTotal dividends (dividends from SMPS): 1,645 hundred million yen (YoY unknown)","jir_category":"","jir_hashtags":"#SumitomoChemical, #DisclosureUpdate, #Governance, #CorporateInformationDisclosure","jir_key_figures":"1) Total dividends (SMPS): 1,645 hundred million yen\n2) Book value reduction of SMPS shares: 1,162 hundred million yen\n3) Recognized as dividend income: 483 hundred million yen","jir_meta_title":"Sumitomo Chemical: Publication of Additional Explanations for the Report | 2026-08-07","jir_meta_description":"Sumitomo Chemical Group issues additional explanations in response to the GCR report. Details on the earnings indicators for the fiscal year ending March 2026, reasonable factors for accounts receivable increases, consistency of dividend treatment, and the financial reporting process.","jir_og_title":"Sumitomo Chemical Publishes Additional Explanations on GCR Report","jir_og_description":"In the August 7 disclosure, views on the points raised and a commitment to ensure financial reporting transparency are highlighted, with references to future disclosure policy and legal responses.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7702,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-98858","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n